

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934.

Date of Report: January 15, 2009  
(Date of earliest event reported)

---

**Oragenics, Inc**

(Exact name of registrant as specified in its charter)

---

**FL**  
(State or other jurisdiction  
of incorporation)

**001-38122**  
(Commission File Number)

**59-3410522**  
(IRS Employer  
Identification Number)

**13700 Progress Blvd**  
(Address of principal executive offices)

**32615**  
(Zip Code)

**386-418-4018**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## ITEM 7.01 REGULATION FD DISCLOSURE

On January 15, 2009, ONI BioPharma Inc.'s ("ONI BioPharma" or the "Company") Chief Executive Officer, Stanley Stein and Chief Scientific Officer, Jeffrey Hillman are scheduled to use a PowerPoint presentation (the "Presentation") and Fact Sheet ("Fact Sheet"), with certain interested persons in Paris, France. The Presentation provides a summary of the Company's product divisions and the technologies within each division, with an emphasis on the recent launch and marketing of EvoraPlus™, which is expected to serve as a revenue base for the other divisions. The Presentation also focused on the recent listing of the Company's common stock on Alternext Paris exchange and the benefits of doing so. The Fact Sheet summarizes certain information from the Presentation.

Copies of the January 15, 2009 slide Presentation and Fact Sheet are attached hereto as Exhibits 99.1 and 99.2 respectively, to this report and are incorporated by reference.

The information in this Current Report on Form 8-K, including the Presentation and Fact Sheet attached hereto respectively as Exhibit 99.1 and Exhibit 99.2, is being furnished pursuant to this Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

By filing this Current Report on Form 8-K and furnishing this information, ONI BioPharma makes no admission as to the materiality of any information in this report. The information contained in the this report is intended to be considered in the context of ONI BioPharma's filings with the SEC and other public announcements that ONI BioPharma makes, by press release or otherwise, from time to time. ONI BioPharma undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any information contained in the Presentation and Fact Sheet should be read in the context of and with due regard to the more detailed information provided in other documents we file with or furnish to the Securities and Exchange Commission, including, but not limited to, our annual report on Form 10-K for the year ended December 31, 2007 and our quarterly report on Form 10-Q for the quarter ended September 30, 2008 and through press releases or through other public disclosure.

## Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

### Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Power Point Presentation dated January 15, 2009
99.2	Fact Sheet dated January 15, 2009

---

## SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 14<sup>th</sup> day of January, 2009.

**ORAGENICS, INC.**

BY: /s/ David B. Hirsch

\_\_\_\_\_  
David B. Hirsch

Chief Financial Officer

---



# CORPORATE OVERVIEW



JANUARY 2009



*This presentation does not constitute an offering of any securities for sale or a solicitation of offers to purchase securities. The Company's securities may not be offered or sold absent registration under applicable securities laws or an exemption from registration. Any public offering of the securities of the Company will be made by means of a prospectus that will contain detailed information about the offering and the Company.*

## Safe Harbor

---

- Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect ONI BioPharma's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include: future costs associated with any potential listing sponsor, those factors set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

## Corporate Mission

ONI BioPharma is a multi-faceted biopharmaceutical company with operations in four divisions:

- Consumer Healthcare
- Diagnostics
- Replacement Therapy
- Antibiotics



ONI is commercializing its first consumer products:

- **Probiora3™**, the first full-care oral probiotic that promotes healthy teeth and gums and whitens teeth and freshens breath.
- **LPT3-04™** for weight loss is in clinical trials and, if successful, should be ready for marketing in 2009.

ONI expects to generate revenue from consumer products in 2009 both in the US and internationally. Proceeds will support the Company's diagnostic, replacement therapy, and antibiotic divisions.

Patents, strategic sales channels, and international partners will support ONI's growth. ONI is developing commercial and research facilities in Mexico and France to support its global strategy. ONI was founded in 1996 by Dr. Jeffrey Hillman, a recognized expert in molecular genetics. The Company is based in Alachua, Florida.

## Financial Highlights

<b>OTCBB:</b>	<b>ORNI</b>
<b>NYSE Alternext Paris:</b>	<b>ALONI</b>
<b>Industry:</b>	<b>Biopharmaceutical</b>
<b>Equity Cap:</b>	<b>\$13.03M (US)</b> <small>As of 1/2/09</small>
<b>Volume:</b>	<b>33,843</b>
<b>Shares Outstanding:</b>	<b>38.3M</b>
<b>Float:</b>	<b>21.6M</b>
<b>Long-term debt:</b>	<b>0</b>
<b>Founded:</b>	<b>1996</b>



## Four Product Divisions

ONI's science has developed into four distinct categories. Technologies complement one another. ONI intends to use revenue generated by initial consumer products to support research and development of longer-term therapies.

- Consumer Healthcare
- DPOLT/Antibiotics Platform
- Diagnostics
- Replacement Therapy








## Technology Overview

## Probiora3™

- Mixture of 3 *natural* beneficial oral bacteria for
  - Maintaining dental (tooth) health
  - Maintaining periodontal (gum) health
  - Whitening teeth
  - Promoting fresh breath



Clinically Proven Probiotic Blend for Improving Oral Health



Healthy,  
Bright  
Smiles

*Modern Innovation, The Way Nature Intended*



EvoraPlus is the first probiotic mint designed to promote optimal gum and tooth health, freshen breath, and gently whiten teeth. EvoraPlus includes patented probiotics that are naturally present in healthy mouths. This unique product has been developed to help restore those beneficial bacteria that have been depleted by fast-food diets and modern-day lifestyles. The beneficial bacteria in EvoraPlus bind to teeth and deep under your gums to fight the bacteria that cause bad breath, unsightly teeth and unhealthy gums.

Unlike other whitening agents and breath fresheners, EvoraPlus is safe for dentures, veneers and porcelain. EvoraPlus is all natural and will not cause tooth sensitivity or gum swelling. EvoraPlus addresses bad breath at the source, instead of masking it.

Using EvoraPlus is quick, easy and safe for all ages. Give your customers their best smiles through innovative oral probiotic supplementation.

ONI BioPharma Inc. (ONI / AMEX)  
Contact Us Today for more information on EvoraPlus  
877-456-0029 • 727-456-0029 • sales@onibiopharma.com

## LPT3-04™ : Weight Loss Agent


---

- Safety and activity established in animals
- Novel MOA - selectively kills white fat cells
- Strong evidence for safety in humans
  - Clinical trial in Q2




## MU1140™ - A Focus Techno

- **Our lead antibiotic**
  - **Novel mechanism of action**
  - **Safe and very active in pilot studies**
    - **MRSA**
    - **Most other gram positive infections**
    - **Mtb, both growing and dormant**
    - **No evidence for development of resistance**
  - **Hard to make by conventional fermentation methods**
    - **DPOLT**




## DPOLT™ - A Focus



- Platform for organic synthesis of MU1140
- Proof of principle completed
- Cost effective GMP production
- Can make analogues of MU1140 and the other 50 known lantibiotics

## IVIAT / CMAT – A Focus

- **Fast, sensitive, superior method for identification of targets for new diagnostics, vaccines and drugs**
  - **Human infections**
  - **Plant infections**
  - **Cancers**
  - **Also applicable to various other problems such as bioscavenging and biofouling**



## SMaRT

---


- Genetically modified *Streptococcus mutans*
  - One-time treatment for lifelong protection against most tooth decay





# Strategy and Forecasted Calendar of Development

## Revenue Model



*\* Consumer Health revenue is expected to support the growth of other business units.*

# Projected Summary Timeline 2009-2013

Commercially Available	2009	2010	2011	2012	2013
Consumer Healthcare	Pro Biora3™ LPT3-04™ Commercially Available EvoraPet™, EvoraKids™, EvoraPLUS™	Regulatory approval & marketing Evora & LPT3-04™ in Europe, Asia, South America			
DPOLT/ Antibiotic Platform	5 molecules made MU1140 IND filed	5 molecules made 1 IND filed	5 molecules made 1 IND filed	5 molecules made 1 IND filed	Market first antibiotic, MU1140
Diagnostic	15 projects completed	15 proj. completed Three 510(k)s filed	15 proj. completed Three 510(k)s filed	15 proj. completed Three 510(k)s filed	15 proj. completed Three 510(k)s filed
Replacement Therapy	Second Phase I clinical trial	Phase II/III clinical trial		Market SMaRT	

# Consumer Healthcare

- **ProBiora3™** - Probiotic mint to promote gum and dental health.
- **LPT3-04™** - Natural weight loss compound to kill white fat cells.

## Benefits/Characteristics:

- **GRAS** – Generally Recognized as Safe status (vs FDA approval)
- Significantly reduces regulatory costs
- Fast to market
- Faster generation of gross and net revenues
- Lower capital requirements
- Marketed in US and internationally (Mexico in early 2009)
- Sales and marketing arrangements in place
- Human and companion animal applications



	2009	2010
<b>Oral Health</b>	ProBiora3™– Finish identity work & mass market companion pet product	Commence marketing upon granting of regulatory exemption status – non-US
<b>Weight Loss</b>	<ul style="list-style-type: none"> <li>▪ Finish all clinical trials</li> <li>▪ Begin selling LPT3-04™</li> <li>▪ Begin seeking regulatory exemptions in non-US markets (Europe, Asia &amp; South America)</li> </ul>	Begin global marketing

# Media and Distribution Strategy

- Consumer Product Manufacturers
- Direct Selling Companies
- Dental Product Companies
- Contract Private Label Companies
- Natural Product Companies
- Pet Product Companies
- Mass Retail
- Internet
- Independent Health Food Stores
- Independent Pharmacies
- Dental Offices
- Direct Response
- Direct Mail
- Government



# EvoraPlus Activity

## Existing Internet & Dental



## Meetings With 50+ Mass Retailers



## Probiotics Market

- Probiotics: live microorganisms, which when administered in adequate amounts, confer a health benefit on the host.
- Generally associated with the gut health, though they have been promoted for urogenital health, irritable bowel syndrome, bladder cancer and to boost the immune system.
- Only 40 probiotic products in the US market in 2005. In last three years more than 250 new products were launched.
- Yakult (Japan) is credited with beginning the probiotics revolution and sales of its lead product in 2007 were estimated at \$2.5 billion.
- In addition to Yakult, major players in this market include Danone, Nestle, Danisco, DSM and Proctor & Gamble.



DANISCO

DSM

P&G

- Americans spent close to \$80 billion on oral healthcare in 2007, with over \$5 billion in OTC products.

**ONI BioPharma has the FIRST probiotics product that represents an entry into the total oral health care market.**



# DPOLT/Antibiotics Platform

- **DPOLT™** - Novel organic chemistry synthesis platform enabling large-scale, cost-effective production of clinical grade MU1140 and 50 other known lantibiotics.

## **Benefits/Characteristics:**

- Overcomes 80+ years of previous failures
- Predicted to lead to new antibiotics with novel mechanisms of action
- Potential substantial antibiotic pipeline
- Replaces current antibiotic treatments that are failing

2009*	2010*	2011*	2012-2013*
MU1140 IND filed and 5 new molecules made	5 new molecules made and 1 new IND filed	5 new molecules made and 1 new IND filed	Market MU1140, 5 new molecules made and 1 new IND filed

\* EXPECTED MILESTONES



# Diagnostics

- **PIVIAT™** - Rapid and sensitive identification of novel targets for use in diagnosis and treatment of human infectious diseases.
- **PCMAT™** - Rapid and sensitive identification of novel targets for diagnostics and therapeutic strategies that address an extraordinary range of medical, agricultural, and industrial applications.

## Benefits/Characteristics:

### Market

- > In Vitro Diagnostics ("IVD") market in excess of \$38 billion with forecasted CAGR of 6.7%.
- > Molecular disease segment growing CAGR 15.4%.  
◆ (Source: Research and Markets, 2007)

### Collaboration

- > Recent collaboration with a major, global-diagnostic company

### Mexico

- > ONI's Mexican subsidiary in conjunction with the premier Instituto de Biotecnología, Universidad Nacional Autónoma de México ("IBUNAM"), will collaborate on a number of PIVIAT™ and PCMAT™ projects. Focus will be on treating problems affecting humans, agriculture, and mining on a global basis.

2009*	2010*	2011*	2012*	2013*
15 proj. completed	15 proj. completed Three 510(k)s filed	15 proj. completed Three 510(k)s filed	15 proj. completed Three 510(k)s filed	15 proj. completed Three 510(k)s filed

\* EXPECTED MILESTONES

# Replacement Therapy

- **SMaRT™** - a single, painless application of a genetically modified bacterial strain for tooth surfaces to protect against tooth decay.

## ***Benefits/Characteristics:***

### **Efficiency**

- Mexico trials = 50% cost savings (vs. US)

### **Regulatory Speed**


- ONI Mexico (subsidiary) should attain faster regulatory access within Mexican government
- Reduced “red-tape” associated with government clearance to clinical trials
- Preventative medicines/treatments typically receive faster acceptance and clearance by governments worldwide

2009*	2010*	2012*
Second Phase I clinical trial	Phase II/III FDA clinical trials	Market SMaRT™

\* EXPECTED MILESTONES

# Timeline

## ONI BioPharma



# Management

## Corporate Structuring

**Stanley B. Stein**, *Chief Executive Officer, President and Director*

- 25 years in securities in biotech & healthcare industry
- Managing Director at Drexel Burnham Lambert, Inc.
- Founded SRS Capital - boutique investment firm; specializing in healthcare
- Principal investment banker in the creation of Fresenius Medical Care AG, the largest renal care business in the world

## Science

**Jeffry Hillman**, *DMD, PhD, Chief Scientific Officer and Director*

- Founded ONI to commercialize the fruits of 25 years of research at the Harvard-affiliated Forsyth Institute in Boston and the University of Florida
- Author of 125+ publications
- Undergraduate training at the University of Chicago; DMD degree from Harvard School of Dental Medicine; PhD from Harvard Medical School

## Legal/Accounting

**David B. Hirsch**, *Chief Financial Officer and Chief Operating Officer*

- Manager in the Restructuring Group at Deloitte and Touche
- Associate at The Cottonwood Group, a venture capital firm in San Mateo, California
- MBA from the Tepper School of Business at Carnegie Mellon University and a JD from Drake University Law School
- Licensed attorney in Florida and Indiana

# Outside Directors –

Expertise in: Management , International Business, Academic Science & Media

## **Rick Welch, Chairman**

- President of Welch Business Solutions and Consulting, LLC in Tampa, Florida
- Director and CFO for the following: Orthopedic Development Corporation, Albiorex, LLC, Medi-Spa's of America, Inc, and Vision Twenty-One
- Previously CFO/Executive Vice-President of Finance and Administration, for Sports and Recreation, Inc.

## **Derek Hennecke, Director**

- Independent Board member and expert in drug development
- Founder and CEO of Xcelience, a formulation and clinical manufacturing contract research company in Tampa, Florida
- 25+ years in the international biotechnology; MDS Pharma Sciences, DSM (contract manufacturing company) (NBD)
- Boehringer Mannheim in NBD
- Work experience in Europe, Egypt, Mexico, Canada, and USA


## **Kevin Sills, Director**

- Independent director Vice President of Pharmaceutical Development of King Pharmaceuticals Research & Development
- 25+ years related experience, novel chemical formulations, clinical supplies management
- Faculty experience at University of North Carolina: Center for Professional Advancement; President of NC Pharmaceutical Discussion Group
- Active member of the Licensing Executives Society and the American Assoc of Pharmaceutical Scientists

## **Dr. Marc Siegel, Director**

- Clinical Associate Professor of Medicine at NYU School of Medicine
  - Medical Director of Doctor Radio with NYU and Sirius Satellite Radio
  - Fox News Medical Contributor
- Columnist for the Los Angeles Times, a member of the Board of Contributors at USA Today, regular contributor to the NY Post, and frequent contributor to the Washington Post, the Wall Street Journal, and Newsday

# Global Expansion



## Why a Listing in Paris?

---

### **An anchor point for the commercial conquest of Europe**

- Significant market : popularity of probiotics among European consumers
- Central location
- Strong scientific and industrial network
- Attractive political environment

### **“Fast Path” to Listing**

- Direct listing (use of SEC filings for Information Document)

### **Tailored market place**

- Listing sponsor
- Exposure as a listed company
- Qualified investors (Small & Mid Caps / health care and biotech)
- Inclusion in the NYSE Euronext Next Biotech index

**Supporting growth in Europe**



## Summary



## Summary

---

- ✓ **Sales & near-term revenue generated from consumer product, Probiora3™.**
- ✓ **Facilities & business relations in the United States, Mexico, South America and Europe.**
- ✓ **Multiple strategies for getting consumer and biotech products to market.**
- ✓ **Targeting global healthcare segments where there is distinct need and growing population.**
- ✓ **Undiscovered by Wall Street.**



## In the News



Probiotics - Topic Overview



Probiotics May Help People Taking Antibiotics



What health benefits do they offer?



What is important to know about Probiotics?



Why Probiotics?

What are Probiotics?



## Investor Contacts

***Global Headquarters:***

Stanley B. Stein  
Chief Executive Officer

**ONI BioPharma, Inc.**

13700 Progress Blvd

Alachua, FL 32615

Ph: (386) 418-4018

[sstein@onibiopharma.com](mailto:sstein@onibiopharma.com)

[www.onibiopharma.com](http://www.onibiopharma.com)

***Investor Contact:***

Axelle Vuillermet

Pierre Laurent

**8 place de la Madeleine**

75008 Paris

Tél. : 01 44 71 94 94

[avuillermet@newcap.fr](mailto:avuillermet@newcap.fr)

[pl Laurent@newcap.fr](mailto:pl Laurent@newcap.fr)

Company:	ONI BioPharma, Inc.
Alternext Paris/OTCBB:	ALONI/ ORNI
Share Price:	\$0.31 *
Equity Cap:	\$11.88M*
Shares Outstanding:	38.31M*
Industry:	Biopharmaceutical
	* As of 12/15/08



## Business Summary

ONI BioPharma is a multi-faceted biopharmaceutical company operating in four divisions:

- Consumer Healthcare
- Diagnostics
- Replacement Therapy
- Antibiotics

ONI is commercializing its consumer products: an oral probiotic to suppress gum disease and tooth decay using ONI's ProBiora3™.

ONI expects to generate revenue from consumer products in 2009 both in the US and internationally. Proceeds will support the Company's diagnostic, replacement therapy, and antibiotic divisions.

Patents, strategic sales channels, and international partners will support ONI's growth. ONI is developing commercial and research facilities in Mexico and France to support its global strategy. ONI currently trades on the OTC Market (OTCBB: ORNI) and is the first US Company to be listed on NYSE Alternext Paris (ALONI). ONI was founded in 1996 by Dr. Jeffrey Hillman, a recognized expert on molecular genetics. The Company is based in Alachua, Florida.

## Global Worldwide Operation



### NYSE Alternext Paris

On December 15, 2008, ONI BioPharma listed on NYSE Alternext Paris as the first US Company listing on this exchange. The listing will further enhance ONI BioPharma's presence in Europe and globally.

## Business Divisions

### Consumer Healthcare

- **ProBiora3™** - Probiotic mint to promote gum and dental health.
- **LPT3-04™** - Natural weight loss compound to kill white fat cells.

#### Benefits/Characteristics:

- GRAS – Generally Recognized as Safe status (vs FDA approval)
- Significantly reduces regulatory costs
- Fast to market
- Faster generation of gross and net revenues
- Lower capital requirements
- Marketed in US and internationally (Mexico in early 2009)
- Sales and marketing arrangements in place
- Human and companion animal applications

### DPOLT/Antibiotics Platform

- **DPOLT™** - Novel organic chemistry synthesis platform enabling large-scale, cost-effective production of clinical grade MU1140 and 50 other known antibiotics.

#### Benefits/Characteristics:

- Overcomes 80+ years of previous failures
- Predicted to lead to new antibiotics with novel mechanisms of action
- Substantial antibiotic pipeline
- Replaces current antibiotic treatments

### Diagnostics

- **PVIAT™** - Rapid and sensitive identification of novel targets for use in diagnosis and treatment of human infectious diseases.
- **PCMAT™** - Rapid and sensitive identification of novel targets for diagnostics and therapeutic strategies that address an extraordinary range of medical, agricultural, and industrial applications.

#### Benefits/Characteristics:

##### Market

- InVivo Diagnostics ("IVD") market in excess of \$38 billion with forecasted CAGR of 6.7%
- Molecular disease segment growing CAGR 15.4%  
  - ◆ (Source: Research and Markets, 2007)

##### Collaboration

- Recent collaboration with a major, global-diagnostic company

##### Mexico

- ONI's Mexican subsidiary in conjunction with the premier Instituto de Biotecnología, Universidad Nacional Autónoma de México ("IBUNAM"), will collaborate on a number of PVIAT™ and PCMAT™ projects. Focus will be on treating indications in humans, agriculture, and mining on a global basis

### Replacement Therapy

- **SMaRT™** - a single, painless application of a genetically modified bacterial strain for tooth surfaces to protect against tooth decay.

#### Benefits/Characteristics:

##### Efficiency

- Mexico trials = 50% cost savings (vs. US)
- Regulatory Speed
- ONI Mexico (subsidiary) should attain faster regulatory access within Mexican government
- Reduced "red-tape" associated with government clearance to clinical trials
- Policy Expediency
- Preventative medicines/treatments typically receive faster acceptance and clearance by governments worldwide

## Management

### **Stanley B. Stein, Chief Executive Officer, President and Director**

- 25 years in securities in biotech & healthcare industry
- Managing Director at Drexel Burnham Lambert, Inc.
- Founded SRS Capital, boutique healthcare investment firm
- Principal investment banker in the creation of Fresenius Medical Care AG, the largest renal care business in the world

### **Jeffrey Hillman, DMD, PhD, Chief Scientific Officer and Director**

- Founded ONI to commercialize the fruits of 25 years of research at the Harvard-affiliated Forsyth Institute in Boston and the University of Florida
- Authored of 125+ publications
- Undergraduate training at the University of Chicago; DMD degree from Harvard School of Dental Medicine; PhD from Harvard Medical School

### **David B. Hirsch, Chief Financial Officer and Chief Operating Officer**

- Manager in the Restructuring Group at Deloitte and Touche
- Associate at The Cottonwood Group, a venture capital firm in San Mateo, California
- MBA from Tepper School of Business at Carnegie Mellon University and JD from Drake University Law School
- Licensed attorney in Florida and Indiana



## Recent Events

- ✦ **December 10, 2008**  
*ONI BioPharma Announces Its Listing on Alternext Paris*
- ✦ **October 13, 2008**  
*Announces Successful Antibiotic Synthesis Using DPOLT Technology*
- ✦ **September 28, 2008**  
*Licenses Unique Gene Targets for Colorectal Cancer*
- ✦ **September 25, 2008**  
*Launches the ProBiora3 Website*
- ✦ **September 17, 2008**  
*Commences Market Launch of Unique Oral Probiotic Product*
- ✦ **June 30, 2008**  
*Appoints New Chief Operational Officer, David B. Hirsch*
- ✦ **June 12, 2008**  
*Closes on \$2,600,000 in Equity Financing*
- ✦ **February 12, 2008**  
*Stanley B. Stein appointed Chief Executive Officer*



## Highlights

- ✓ Sales & near-term revenue generated from consumer products, ProBiora3™.
- ✓ Facilities & business relations in the United States, Mexico, South America and Europe.
- ✓ Multiple strategies for getting consumer and biotech products to market.
- ✓ Targeting healthcare segments where there is distinct need and growing population.

### Global Headquarters:

Stanley B. Stein  
Chief Executive Officer  
ONI BioPharma, Inc.  
13700 Progress Blvd  
Alachua, FL 32615  
Ph: (386) 418-4018  
[sstein.onibiopharma.com](mailto:sstein.onibiopharma.com)  
[www.onibiopharma.com](http://www.onibiopharma.com)

### Investor Contact:

Axelle Vuillermet / Pierre Laurent  
NewCap.  
8 place de la Madeleine  
75008 Paris  
Tél. : 01 44 71 94 94  
[oni@newcap.fr](mailto:oni@newcap.fr)

*This presentation does not constitute an offering of any securities for sale or a solicitation of offers to purchase securities. The Company's securities may not be offered or sold absent registration under applicable securities laws or an exemption from registration. Any public offering of the securities of the Company will be made by means of a prospectus that will contain detailed information about the offering and the Company.*



